

Cognitive Impairment Therapeutic Pipeline Market Review, H2 2016

Cognitive Impairment Treatment Pipeline Review H2 2016

PUNE, INDIA, October 21, 2016

/EINPresswire.com/ -- The report provides comprehensive information on the therapeutics under development for [Cognitive Impairment Associated With Schizophrenia \(CIAS\)](#), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cognitive Impairment Associated With Schizophrenia (CIAS) and features dormant and discontinued projects.



WISE GUY
REPORTS

Norah Trent Partner Relations & Marketing Manager

✉ sales@wiseguyreports.com

☎ Ph: +1-646-845-9349 (US) Ph: +44 208 133 9349 (UK)

🌐 <https://www.linkedin.com/company/4828928>

🐦 <https://twitter.com/WiseGuyReports>

📘 <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Wise.Guy.

Get Sample Report @ <https://www.wiseguyreports.com/sample-request/619292-cognitive-impairment-associated-with-schizophrenia-cias-pipeline-review-h2-2016>

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape of Cognitive Impairment Associated With Schizophrenia (CIAS)
- The report reviews pipeline therapeutics for Cognitive Impairment Associated With Schizophrenia (CIAS) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Cognitive Impairment Associated With Schizophrenia

(CIAS) therapeutics and enlists all their major and minor projects

- The report assesses Cognitive Impairment Associated With Schizophrenia (CIAS) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Cognitive Impairment Associated With Schizophrenia (CIAS)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Cognitive Impairment Associated With Schizophrenia (CIAS)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cognitive Impairment Associated With Schizophrenia (CIAS) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Cognitive Impairment Associated With Schizophrenia (CIAS) Overview 10

Therapeutics Development 11

Pipeline Products for Cognitive Impairment Associated With Schizophrenia (CIAS) - Overview 11

Cognitive Impairment Associated With Schizophrenia (CIAS) - Therapeutics under Development by Companies 12

Cognitive Impairment Associated With Schizophrenia (CIAS) - Pipeline Products Glance 14

Clinical Stage Products 14

Early Stage Products 15

Cognitive Impairment Associated With Schizophrenia (CIAS) - Products under Development by Companies 16

Cognitive Impairment Associated With Schizophrenia (CIAS) - Companies Involved in Therapeutics Development 18

AbbVie Inc. 18

Amarantus Bioscience Holdings, Inc. 19

Astellas Pharma Inc. 20

AstraZeneca Plc 21

Bristol-Myers Squibb Company 22

Coronis Partners Ltd. 23

Eli Lilly and Company 24

FORUM Pharmaceuticals Inc. 25

H. Lundbeck A/S 26

Intra-Cellular Therapies, Inc. 27

Iproteos S.L. 28

Luc Therapeutics, Inc. 29

Neuralstem, Inc. 30
Pfizer Inc. 31

Access Report @ <https://www.wiseguyreports.com/reports/619292-cognitive-impairment-associated-with-schizophrenia-cias-pipeline-review-h2-2016>

Get in touch:

LinkedIn: www.linkedin.com/company/4828928

Twitter: <https://twitter.com/WiseGuyReports>

Facebook: <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Norah Trent

wiseguyreports

+1 646 845 9349 / +44 208 133 9349

[email us here](#)

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2019 IPD Group, Inc. All Right Reserved.